

## DAFTAR PUSTAKA

- Abraldes, J. G., Albillos, A., Bañares, R., Turnes, J., & González, R., 2009. Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal. *YGAST*. 136(5): 1651–1658.
- Adamson J, Ebrahim S, Dieppe P, Hunt K. 2006. Prevalence and risk factors for joint pain among men and women in the West of Scotland Twenty-07 Study. *Ann Rheum Dis*; 65:520–4.
- Afdhal, N.H., Bacon, B.R., Patel, K., Garg, J., McHutchison, J.G., Lawitz, E.J., Gordon, S.C., Nelson, D.R., Challies, T.L., Nasser, I., 2015. Accuracy Of Fibroscan, Compared With Histology, In Analysis Of Liver Fibrosis In Patients With Hepatitis B Or C. *A United States Multicenter Study*;13(4):772-9.e1-3.
- Badiu, R., Bucsa, C., Mogosan, C., Dumitrascu, D. 2016. Statin Drug-Drug Interactions In A Romanian Community Pharmacy. *Chujul Medical* Vol. 89 no. 2: 273-278.
- Bataller, R., & Brenner, D. A., 2005. Science in medicine: Liver fibrosis. *J Clin Invest* ;115(2): 211.
- Blachier, M., Leleu, H., Peck-radosavljevic, M., Valla, D., & Roudot-thoraval, F., 2013. Special Review The burden of liver disease in Europe : A review of available epidemiological data. *Journal of Hepatology*. 58(3):593–608.
- Cadranel, J-F., Rufat, P., Doges, F. 2000. Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey. *Hepatology Vol. 32*, No. 3: 477-481.
- Catherine, A. P. dan Sanjiv, C., 1998. Cirrhosis and portal hipertension In: S. Lawrence dan B. Emmet (eds.) Handbook of liver disease.
- Cecchi, F., Mannoni, A., Molino-Lova, R., Ceppatelli, S., Benvenuti, E., Bandinelli, S., Lauretani, F., Macchi, C., Ferrucci, L. 2008. Epidemiology Of Hip And Knee Pain In A Community Based Sample Of Italian Persons Aged 65 And Older. *Osteoarthritis Cartilage* ; 16(9): 1039–1046.
- Chung, R. T. dan Podolsky, D. K., 2005. Cirrhosis and its complication. In: D. L. Kasper, A. S. Fauci, D. L. Longo, *et al.* (eds.) Harrison' principles of internal medicine. p: 1971. McGraw-Hill, New York.
- Dancygier, H., 2010. Clinical scoring systems. In: H. Dancygier (ed.) Clinical Hepatology. p: 289-290. Springer, Verlag Berlin Heidelberg.
- Dancygier, H., 2010. Liver Cirrhosis. In: H. Dancygier (ed.) Clinical Hepatology. : 949-966. Springer, Verlag Berlin Heidelberg.
- Davis, G. L., Alter, M. J., Serag, H. E. L., Poynard, T., & Jennings, L. W., 2010. Aging of Hepatitis C Virus ( HCV )-Infected Persons in the United States : A Multiple Cohort Model of HCV Prevalence and Disease Progression.

*YGAST*. 138(2): 513–521.

- Dawson J, Linsell L, Zondervan K, Rose P, Randall T, Carr A, et al. 2004. Epidemiology of hip and knee pain and its impact on overall health status in older adults. *Rheumatology*; 43:497–504.
- Desmet, V. J., & Roskams, T., 2004. Cirrhosis reversal : A Duel Between Dogma And Myth. *Journal of Hepatology*; 40:860–867.
- Dietrich, C. F., 2010. Ultrasonography. In: H. Danczygier (ed.) *Clinical Hepatology*. p:359-404. Springer, Verlag Berlin Heidelberg.
- El-Hariri, M., Abd El Megid, A.G., Taha Ali, T.F., Hassany, M. 2017. Diagnostic Value Of Transient Elastography (Fibroscan) In The Evaluation Of Liver Fibrosis In Chronic Viral Hepatitis C: Comparison To Liver Biopsy. *The Egyptian Journal of Radiology and Nuclear Medicine*; 48 (2017) 329–337.
- Faber, J., & Fonseca, L. M. 2014. How Sample Size Influences Research Outcomes. *Dental Press J Orthod*; 19(4):27-9.
- Lakner, A. M., Steuerwald, N. M., Walling, T. L., Ghosh, S., Li, T., ... Schrum, L. W., 2012. Inhibitory Effects of MicroRNA 19b in Hepatic Stellate Cell-Mediated Fibrogenesis. *Official Journal of AASLD*; 14891: 1–11.
- Foucher, J., Chanteloup, E., Vergniol, J., Caste´ra, L., Le Bail, B., Adhoute, X., et al., 2006. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut*. 55:403–408.
- Friedman, S. L., 2004. Mechanisms of Disease : mechanisms of hepatic fibrosis and therapeutic implications. *Nature* ;1(2): 98-100.
- Garcia-tSao, G., & Lim, J., 2009. Management and Treatment of Patients With Cirrhosis and Portal Hypertension : Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Nature* ;104(7): 1802–1829.
- Gea, V.H., Friedman, S.L. 2011. The Annual Review of Pathology: Pathogenesis of Liver Fibrosis. *Annu. Rev. Pathol. Mech. Dis*; 6:425–56.
- Ghadir, M. R., Riahin, A. A., Havaspour, A., Nooranipour, M. dan Habibinejad, A. A., 2010. The Relationship between Lipid Profile and Severity of Liver Damage in Cirrhotic Patients. *Hepat Mon*. 10:285 - 288.
- Golomb, B.A. and Evans, M.A. 2008. Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism. *Am J Cardiovasc Drugs* ; 8(6): 373–418.
- Hashemi, S.A., Lavian, S.M., dan Gholami-Fesharaki, M. 2016. Assessment Of Transient Elastography (Fibroscan) For Diagnosis Of Fibrosis In Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Caspian J Intern Med* ; 7(4): 242-252.
- Jacobson, I.M., Russo, M.W. 2004. How to Use Statins in Patients with Chronic Liver Disease. *Cleveland Clinical Journal of Medicine* ; 71(1): 58–62.

- Janicko, M., Drazilova, S., Pella, D., Fedacko, J., Jarcuska, P., Janicko, M., Jarcuska, P., 2016. Pleiotropic effects of statins in the diseases of the liver. *World Journal of Gastroenterology* ; 22(27): 6201–6213.
- Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers MF, et al. 2000. Systemic risk factors for osteoarthritis. In: Felson conference chair DT, Ed. Osteoarthritis: new insights. Part 1: the disease and its risk factors. *Ann Intern Med*; 133:637–9.
- Kemp, W. and Robert, S. 2013. Fibroscan and Transient Elastography. *Aust.Fam. Physician*; 42(7):468-71.
- Kumar, S., Grace, N. D., Qamar, A. A. 2014. Statin Use in Patients with Cirrhosis : A Retrospective Cohort Study. *Dig Dis Sci*; 59:1958–1965.
- Lenaz G, D'Aurelio M, Merlo Pich M, et al. 2000. Mitochondrial bioenergetics in aging. *Biochim Biophys Acta*;1459:397–404.
- Link E, Parish S, Armitage J, et al. 2008. SLCO1B1 variants and statin-induced myopathy--a genomewide study. *N Engl J Med*;359:789–99.
- Lochs, H., Plauth, M., 1999. Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral Nutrition consensus and beyond. *Curr Opin Clin Nutr Metab Care*. 4:345-349.
- Malizia, G., D'Amico, G. 2016. Statins in Cirrhosis: The Magic Pill?. *Hepatology*. Vol. 63, No. 6: 2047-2049.
- Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Israel, B., 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label follow-up study. *Lancet* ;381: 464-478.
- Marrone, G., Maeso-díaz, R., García-cardena, G., Abalde, J. G., García-pagán, J. C., Bosch, J., & Gracia-sancho, J., 2014. KLF2 exerts anti fibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. *Gut*;0:1–10.
- McCormick, P., 2011. Hepatic Cirrhosis. In : James S.D., Anna S.F., Andrew .K.B., E. Jenny H (eds). *Sherlock's Diseases Of The Liver And Biliary System* 12Th Ed. p: 103-117. Wiley-Blackwell, New Jersey.
- Mueller, S. and Sandrin, L. 2010. Liver stiffness: a novel parameter for the diagnosis of liver disease. *Hepatic Medicine: Evidence and Research* ;2: 49–67.
- Mulyana, Edi. 2013. Tingkat Keberhasilan Pengukuran Dengan Transient Elastography Pada Pasien Non-Alcoholic Fatty Liver Disease Dengan Obesitas Dan Faktor - Faktor Yang Mempengaruhinya. Tersedia dari: <http://lib.ui.ac.id/opac/themes/libri2/detail.jsp>.
- Mura, V. La, Nicolini, A., Tosetti, G., Primignani, M., Mura, V. La, Nicolini, A.,

- & Tosetti, G., 2015. Cirrhosis and portal hypertension : The Importance Of Risk Stratification, The Role Of Hepatic Venous Pressure Gradient Measurement. *World J Hepatol*; 7(4): 688-695.
- Nurdjanah S., 2009. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. Edisi V Jilid I. Hal:668-673. Jakarta. Interna Publishing.
- Oakley, F., Meso, M., Iredale, J. P., Mann, D. A., 2005. Inhibition of Inhibitor of kappaB Kinases Stimulates Hepatic Stellate Cell Apoptosis and Accelerated Recovery From Rat Liver Fibrosis. *Gastroenterology*;128(1):108–120.
- Okuyama, H., Langsjoen, P.H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T., Uchino, H. 2015. Statins stimulate Atherosclerosis and heart Failure: pharmacological Mechanisms. *Expert rev. Clin. Pharmacol.* 8(2),189–199.
- Papers, J. B. C., & Bieker, J. J., 2001. Kruppel-like Factors : Three Fingers in Many Pies. *The Journal of Biological Chemistry*;4(26):34355–34358.
- Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A., 2014. R p Liver fibrosis and repair : immune regulation of wound healing in a solid organ. *Nature Publishing Group*.14(3):181–194.
- Perazzo, H., Veloso, V, G., Griesztejn, B., Hyde, C., & Castro, R. 2015. Factors That Could Impact on Liver Fibrosis Staging by Transient Elastography. *International Journal of Hepatology Vol 2015*: 1-4.
- Pieri, G., Agarwal, B., & Burroughs, A.K. 2014. C-Reactive Protein And Bacterial Infection In Cirrhosis. *Ann Gastroenterol*; 27 (2): 113-120.
- Pinzani, M., Rombouts, K., & Colagrande, S., 2005. Fibrosis in chronic liver diseases : diagnosis and management. *42*:22–36.
- Prabowo, N, A. 2015. Pengaruh simvastatin terhadap kadar *transforming Growth factor  $\beta$ 1*, skor *fibroskan* dan skor *aspartat Transaminase to platelet index* Pada pasien sirosis hati. Universitas Negeri Surakarta. Tersedia dari: <https://digilib.uns.ac.id>.
- Quinaglia e Silva, J.C., Munhoz, D.B., Morato, T.N., Gurgel, A., Macedo, A.C.T., Sever, P., Sposito, A.C. 2009. Effect of beta blockers (metoprolol or propranolol) on effect of Simvastatin in lowering c-reactive protein in Acute myocardial infarction. *Am.J. Cardiol*;103:461– 463.
- Rockey, D. O. N. C., 2005. Antifibrotic Therapy in Chronic Liver Disease. *Clinical Gastroenterology And Hepatology*;3:95–107.
- Scaglione, S., Kliethermes, S., Cao, G., Shoham, D., Durazo, R., Luke, A., & Volk, M. L., 2015. The Epidemiology of Cirrhosis in the United States A Population-based Study. *J. Clin. Gastroenterol*;49(8): 690–696.
- Schech S, Graham D, Staffa J, et al. 2007. Risk factors for statin-associated rhabdomyolysis. *Pharmacoepidemiol. Drug. Saf*;16:352–8.

- Schuppan, D., Afdhal, N. H., & Israel, B., 2008. Seminar Liver cirrhosis. *Lancet*; 371: 838–51.
- Schuppan, D., Krebs, A., Bauer, M., & Hahn, E. G., 2003. Hepatitis C and liver fibrosis. *Nature*; 10:S59–S67.
- Sherlock, S., Dooley, JD., 2002. Hepatic Cirrhosis. In: S. Sherlock and J. D. Dooley (eds.) *Diseases of the Liver and Biliary System* 11<sup>th</sup> ed. p: 706. Blackwell, London.
- Simon, T. G., King, L. Y., & Chung, R. T., 2015. Coagulation and fibrosis : A Potential Non-Negligible Target of Statins In Chronic Hepatitis. *Journal of Hepatology*;63(1): 279.
- Sporea, I., Srili, R., Deleanu, A., Tudora, A., Popescu, A., Curescu, M., & Bota, S. 2010. Liver Stiffness Measurements In Patients With Hbv Vs Hcv Chronic Hepatitis: A Comparative Study. *World J Gastroenterol*; 16(38): 4832-4837.
- Starr, S. P., Raines, D., State, L., Orleans, N., & Orleans, N., 2011. Cirrhosis: Diagnosis, Management, and Prevention; *Am. Fam. Physician*;4(12):1353–9.
- Sutadi, S. M. 2003. Sirosis Hepatis, Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Sumatera Utara, Medan. Tersedia dari : <http://library.usu.ac.id>
- Thomas, R. R. dan Ahsan, M. B., 2001. Preventive strategies in chronic liver disease. *Am. Fam. Physician*; 64:1555-1560.
- Thumboo J, Chew LH, Lewin-Koh SC. 2002. Socioeconomic and psychosocial factors influence pain or physical function in Asian patients with knee or hip osteoarthritis. *Ann. Rheum. Dis.*; 61:1017–20.
- Tsochatzis, E. A., Bosch, J., & Burroughs, A. K., 2014. Liver cirrhosis. *The Lancet*: 6736(14): 1–13.
- Vita AJ, Terry RB, Hubert HB, Fries JF. 1998. Aging, health risks, and cumulative disability. *N.Engl.J.Med*; 338:1035–41.
- Wang, W., Zhao, C., Zhou, J., Zhen, Z., Wang, Y., & Shen, C. 2013. Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis - Related Liver Fibrosis. *Plosone*;8(10): 1–11.
- Wilder, Julius and Patel, Keyur. 2014. The clinical utility of FibroScan as a noninvasive diagnostic test for liver disease. *Med.Devices (Auckl)*;7:107-114.
- Wolf, D. C., 2009. *Cirrhosis*. Tersedia dari: URL: <http://emedicine.medscape.com/article/185856-overview>
- Zhou, W., Zhang, Q., & Qiao, L., 2014. Pathogenesis of liver cirrhosis. *World J Gastroenterol*; 20(23): 7312–7324.